TheraRadar
Data updated: May 26, 2026

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER (cefoxitin sodium)

Trial Activity: Stable 3 active trials
Infectious Disease Approved 2006-03-10

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER is indicated for the treatment of Lower Respiratory Tract Infection; Pneumonia; Lung Abscess; Urinary Tract Infection; Intra-Abdominal Infection; Peritonitis; Intra-Abdominal Abscess; Gynecological Infection; Endometritis; Pelvic Cellulitis.

Source: FDA Label • B BRAUN
Jump to: Indications Approvals Trials Competitors Similar Safety Patents

Development Insights

The University of Queensland conducting 2 trials (33%)
11 indications explored (Broad Platform)
→ mycobacterium abscessus pulmonary disease (1 trials)
→ mycobacterium abscessus infection (1 trials)
→ non-tuberculous mycobacterial (ntm) infections (1 trials)
1
Indication
--
Phase 3 Trials
20
Years on Market

Details

Status
Prescription
First Approved
2006-03-10
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

B BRAUN
Active Ingredient: CEFOXITIN SODIUM

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER Approval History

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
14 FDA actions from 2006 to 2019
Jul 2019 SUPPL
Label · Labeling
FDA Letter Label
Jun 2013 SUPPL
Label · Labeling
FDA Letter Label
Dec 2012 SUPPL
Mfg · Manufacturing (CMC)

What CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER Treats

10 indications

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER is approved for 10 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Lower Respiratory Tract Infection
  • Pneumonia
  • Lung Abscess
  • Urinary Tract Infection
  • Intra-Abdominal Infection
  • Peritonitis
  • Intra-Abdominal Abscess
  • Gynecological Infection
Source: FDA Label

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Indication competitors

10

Same indication, different mechanism — what else might this patient receive?

CONTEPO
MEITHEAL
2025 2 indic.
ENFLONSIA
Merck
2025 1 indic.
Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CEFOXITIN IN PLASTIC CONTAINER
CEFOXITIN SODIUM
10 shared
SAMSON MEDCL
Shared indications:
Lower Respiratory Tract InfectionPneumoniaLung Abscess +7 more
CLEOCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE
6 shared
Pfizer
Shared indications:
Intra-abdominal InfectionPeritonitisIntra-abdominal Abscess +3 more
CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE
5 shared
MICRO LABS
Shared indications:
Intra-Abdominal InfectionPeritonitisIntra-Abdominal Abscess +2 more
View all 20 similar drugs Pro
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER FDA Label Details

Indications & Usage

FDA Label (PDF)

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER is indicated for the treatment of Lower Respiratory Tract Infection; Pneumonia; Lung Abscess; Urinary Tract Infection; Intra-Abdominal Infection; Peritonitis; Intra-Abdominal Abscess; Gynecological Infection; Endometritis; Pelvic Cellulitis.

Track CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA065214 → Label: DailyMed → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment